Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC in Pediatric Acute Liver Failure
NCT00248625Phase 3Completed
- Sponsor
- University of Pittsburgh
- Start
- Jan 2000
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in acute liver failure (ALF) comparing N-acetylcysteine (NAC) with Placebo (2 arms). Primary endpoint: Survival at 1 year. Started Jan 2000; status: completed.
02
Drugs
acetylcysteine
03
Conditions
acute liver failure (ALF)
Beyond the preview
Go deeper on NCT00248625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00248625.